Literature DB >> 32444392

Early T Cell Activation Metrics Predict Graft-versus-Host Disease in a Humanized Mouse Model of Hematopoietic Stem Cell Transplantation.

Nicholas J Hess1, Amy W Hudson2, Peiman Hematti3, Jenny E Gumperz4.   

Abstract

Acute graft-versus-host disease (GVHD) is a frequent complication of hematopoietic transplantation, yet patient risk stratification remains difficult, and prognostic biomarkers to guide early clinical interventions are lacking. We developed an approach to evaluate the potential of human T cells from hematopoietic grafts to produce GVHD. Nonconditioned NBSGW mice transplanted with titrated doses of human bone marrow developed GVHD that was characterized by widespread lymphocyte infiltration and organ pathology. Interestingly, GVHD was not an inevitable outcome in our system and was influenced by transplant dose, inflammatory status of the host, and type of graft. Mice that went on to develop GVHD showed signs of rapid proliferation in the human T cell population during the first 1-3 wk posttransplant and had elevated human IFN-γ in plasma that correlated negatively with the expansion of the human hematopoietic compartment. Furthermore, these early T cell activation metrics were predictive of GVHD onset 3-6 wk before phenotypic pathology. These results reveal an early window of susceptibility for pathological T cell activation following hematopoietic transplantation that is not simply determined by transient inflammation resulting from conditioning-associated damage and show that T cell parameters during this window can serve as prognostic biomarkers for risk of later GVHD development.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32444392      PMCID: PMC7329317          DOI: 10.4049/jimmunol.2000054

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

Review 1.  Cytokines in Graft-versus-Host Disease.

Authors:  Andrea S Henden; Geoffrey R Hill
Journal:  J Immunol       Date:  2015-05-15       Impact factor: 5.422

2.  Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease.

Authors:  Motoko Koyama; Rachel D Kuns; Stuart D Olver; Neil C Raffelt; Yana A Wilson; Alistair L J Don; Katie E Lineburg; Melody Cheong; Renee J Robb; Kate A Markey; Antiopi Varelias; Bernard Malissen; Günter J Hämmerling; Andrew D Clouston; Christian R Engwerda; Purnima Bhat; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Nat Med       Date:  2011-11-29       Impact factor: 53.440

3.  The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease.

Authors:  Hrishikesh K Srinagesh; Umut Özbek; Urvi Kapoor; Francis Ayuk; Mina Aziz; Kaitlyn Ben-David; Hannah K Choe; Zachariah DeFilipp; Aaron Etra; Stephan A Grupp; Matthew J Hartwell; Elizabeth O Hexner; William J Hogan; Alexander B Karol; Stelios Kasikis; Carrie L Kitko; Steven Kowalyk; Jung-Yi Lin; Hannah Major-Monfried; Stephan Mielke; Pietro Merli; George Morales; Rainer Ordemann; Michael A Pulsipher; Muna Qayed; Pavan Reddy; Ran Reshef; Wolf Rösler; Karamjeet S Sandhu; Tal Schechter; Jay Shah; Keith Sigel; Daniela Weber; Matthias Wölfl; Kitsada Wudhikarn; Rachel Young; John E Levine; James L M Ferrara
Journal:  Blood Adv       Date:  2019-12-10

4.  Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease.

Authors:  Yi Zhang; Jean-Pierre Louboutin; Jiang Zhu; Adam J Rivera; Stephen G Emerson
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

5.  MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.

Authors:  Hannah Major-Monfried; Anne S Renteria; Attaphol Pawarode; Pavan Reddy; Francis Ayuk; Ernst Holler; Yvonne A Efebera; William J Hogan; Matthias Wölfl; Muna Qayed; Elizabeth O Hexner; Kitsada Wudhikarn; Rainer Ordemann; Rachel Young; Jay Shah; Matthew J Hartwell; Mohammed S Chaudhry; Mina Aziz; Aaron Etra; Gregory A Yanik; Nicolaus Kröger; Daniela Weber; Yi-Bin Chen; Ryotaro Nakamura; Wolf Rösler; Carrie L Kitko; Andrew C Harris; Michael Pulsipher; Ran Reshef; Steven Kowalyk; George Morales; Ivan Torres; Umut Özbek; James L M Ferrara; John E Levine
Journal:  Blood       Date:  2018-03-15       Impact factor: 22.113

6.  Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance.

Authors:  Edward S Morris; Kelli P A MacDonald; Vanessa Rowe; Diana H Johnson; Tatjana Banovic; Andrew D Clouston; Geoffrey R Hill
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

7.  Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease.

Authors:  L Pan; J Delmonte; C K Jalonen; J L Ferrara
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113

8.  Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

Authors:  Scott R Solomon; Andrew St Martin; Nirav N Shah; Giancarlo Fatobene; Monzr M Al Malki; Karen K Ballen; Asad Bashey; Nelli Bejanyan; Javier Bolaños Meade; Claudio G Brunstein; Zachariah DeFilipp; Richard E Champlin; Ephraim J Fuchs; Mehdi Hamadani; Peiman Hematti; Christopher G Kanakry; Joseph P McGuirk; Ian K McNiece; Stefan O Ciurea; Marcelo C Pasquini; Vanderson Rocha; Rizwan Romee; Sagar S Patel; Sumithira Vasu; Edmund K Waller; John R Wingard; Mei-Jie Zhang; Mary Eapen
Journal:  Blood Adv       Date:  2019-10-08

9.  A Humanized Mouse Model Generated Using Surplus Neonatal Tissue.

Authors:  Matthew E Brown; Ying Zhou; Brian E McIntosh; Ian G Norman; Hannah E Lou; Mitch Biermann; Jeremy A Sullivan; Timothy J Kamp; James A Thomson; Petros V Anagnostopoulos; William J Burlingham
Journal:  Stem Cell Reports       Date:  2018-03-22       Impact factor: 7.765

10.  Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation.

Authors:  Zhanzhuo Li; Agnieszka Czechowicz; Amelia Scheck; Derrick J Rossi; Philip M Murphy
Journal:  Nat Commun       Date:  2019-02-06       Impact factor: 14.919

View more
  5 in total

1.  Possible roads to improve hemophagocytic lymphohistiocytosis outcome.

Authors:  Pietro Merli; Michael B Jordan; Franco Locatelli
Journal:  Blood Adv       Date:  2020-12-22

Review 2.  GVHD Pathogenesis, Prevention and Treatment: Lessons From Humanized Mouse Transplant Models.

Authors:  Nicholas J Hess; Matthew E Brown; Christian M Capitini
Journal:  Front Immunol       Date:  2021-07-29       Impact factor: 7.561

Review 3.  Insights into mechanisms of graft-versus-host disease through humanised mouse models.

Authors:  Amal Elhage; Chloe Sligar; Debbie Watson; Ronald Sluyter; Peter Cuthbertson
Journal:  Biosci Rep       Date:  2022-09-30       Impact factor: 3.976

4.  iNKT cells coordinate immune pathways to enable engraftment in nonconditioned hosts.

Authors:  Nicholas J Hess; Nikhila S Bharadwaj; Elizabeth A Bobeck; Courtney E McDougal; Shidong Ma; John-Demian Sauer; Amy W Hudson; Jenny E Gumperz
Journal:  Life Sci Alliance       Date:  2021-06-10

5.  Different Human Immune Lineage Compositions Are Generated in Non-Conditioned NBSGW Mice Depending on HSPC Source.

Authors:  Nicholas J Hess; Payton N Lindner; Jessica Vazquez; Samuel Grindel; Amy W Hudson; Aleksandar K Stanic; Akihiro Ikeda; Peiman Hematti; Jenny E Gumperz
Journal:  Front Immunol       Date:  2020-10-19       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.